The True Costs of the 21-Gene Assay in a Cohort of 1,000 Patients
06:41 Share

This podcast addresses the clinical implications of the high cost of the 21-gene assay in women with ER-positive, node-negative breast cancer.

Related Article: Population-Based Study to Determine the Health System Costs of Using the 21-Gene Assay)